Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 14/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | DTYMK | P23919 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30940044 | 1.00 | L3MBTL1 (0.47) | L3MBTL1ELANEBRD4DTYMKPOLB | |
| SCHEMBL4569771 | 0.92 | L3MBTL1 (0.50) | L3MBTL1ELANEBRD4DTYMKPOLB | |
| SCHEMBL4572234 | 0.90 | L3MBTL1 (0.46) | L3MBTL1ELANEBRD4DTYMKPOLB | |
| SCHEMBL30458558 | 0.90 | ELANE (0.46) | L3MBTL1ELANEBRD4DTYMKPOLB | |
| SCHEMBL1267232 | 0.90 | ELANE (0.46) | L3MBTL1ELANEBRD4DTYMKPOLB | |
| SCHEMBL3762275 | 0.87 | ELANE (0.47) | L3MBTL1ELANEBRD4DTYMKPOLB | |
| SCHEMBL4192135 | 0.86 | L3MBTL1 (0.54) | L3MBTL1ELANEBRD4DTYMKPOLB | |
| SCHEMBL3757166 | 0.85 | ELANE (0.43) | L3MBTL1ELANEBRD4DTYMKPOLB | |
| SCHEMBL31219308 | 0.83 | ELANE (0.47) | L3MBTL1ELANEDTYMKPOLB | |
| SCHEMBL13425915 | 0.83 | ELANE (0.47) | L3MBTL1ELANEDTYMKPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409542-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-12-12 | — | — | US | disclosed |
| CN-108137542-B | Pyridone dicarboxamides as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| WO-2018233526-A9 | CSF1R INHIBITOR, AND MANUFACTURING METHOD THEREFOR AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-10428026-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| US-10428026-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-10-01 | — | — | US | disclosed |
| US-20180258044-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-09-13 | — | — | US | disclosed |
| WO-2017037116-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-09 | — | — | WO | disclosed |
| US-9181261-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150141428-A1 | TrkA Kinase Inhibitors, Compositions and Methods Thereof | MERCK SHARP & DOHME CORP. (US) | 2015-05-21 | — | — | US | disclosed |
| EP-2858501-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | Merck Sharp & Dohme Corp. (US) | 2015-04-15 | — | — | EP | disclosed |
| CN-102066372-B | 5, 6-membered heteroaryl bicyclic compounds containing a urea group as kinase inhibitors | ASCEPION PHARMACEUTICALS INC | 2014-09-17 | — | — | CN | disclosed |
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| WO-2013176970-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20120190701-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | disclosed |
| CN-102066372-A | 5, 6-membered heteroaryl bicyclic compounds containing a urea group as kinase inhibitors | ASCEPION PHARMACEUTICALS INC | 2011-05-18 | — | — | CN | disclosed |
| WO-2011023081-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | ASCEPION PHARMACEUTICALS, INC. (CN) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428026-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | BRD4, BRD3, BRDT | L3MBTL1 4684/4885ELANE 1529/4885BRD4 1/4885 |
| US-20120190701-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | L3MBTL1 3966/4885ELANE 1325/4885BRD4 509/4885 |
| US-20240409542-A1 | NOVEL COMPOUNDS | CD47, GPR119, LRBA | L3MBTL1 3300/4885ELANE 266/4885BRD4 542/4885 |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | FLT3, CSF1R, EPHA2 | L3MBTL1 4116/4885ELANE 2008/4885BRD4 2118/4885 |
| US-20150141428-A1 | TrkA Kinase Inhibitors, Compositions and Methods Thereof | NGF, NGFR, NTRK1 | L3MBTL1 2939/4885ELANE 2672/4885BRD4 534/4885 |
| US-20180258044-A1 | PYRIDINONE DICARBOXAMIDE FOR USE AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRDT | L3MBTL1 4684/4885ELANE 1529/4885BRD4 1/4885 |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | BRD4, BRD3, BRDT | L3MBTL1 4684/4885ELANE 1529/4885BRD4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.